Previous Close | 178.1 |
1-Year Change | 75.9% |
6-Months Change | 5.23% |
3-Months Change | -9.83% |
Moving Avg (50d) | 180.03 |
Moving Avg (200d) | 174.64 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 5.02B |
Beta (3-Years) | 1.5 |
Revenue Growth (ttm) | % |
Net Profit Margin (ttm) | -348.43% |
Return On Assets (ttm) | -3.77% |
EPS (ttm) | -1.47 |
PE Ratio (ttm) | -121.16 |
Dividend Yield | % |
Asset Description: | Krystal Biotech, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-12 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
181.662 | 187.005 | 190.567 | 195.91 | 204.815 | 213.72 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |